Chen Haihong, Wang Yaohong, Wang Weishan, Cao Ting, Zhang Lu, Wang Zhengduo, Chi Xuran, Shi Tong, Wang Huangwei, He Xinwei, Liang Mindong, Yang Mengxue, Jiang Wenyi, Lv Dongyuan, Yu Jiaming, Zhu Guoliang, Xie Yongtao, Gao Bei, Wang Xinye, Liu Xueting, Li Youyuan, Ouyang Liming, Zhang Jingyu, Liu Huimin, Li Zilong, Tong Yaojun, Xia Xuekui, Tan Gao-Yi, Zhang Lixin
State Key Laboratory of Bioreactor Engineering and School of Biotechnology, East China University of Science and Technology, Shanghai, China.
State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Nat Biotechnol. 2024 Jun 5. doi: 10.1038/s41587-024-02267-3.
Porphyrins and their derivatives find extensive applications in medicine, food, energy and materials. In this study, we produced porphyrin compounds by combining Rhodobacter sphaeroides as an efficient cell factory with enzymatic catalysis. Genome-wide CRISPRi-based screening in R. sphaeroides identifies hemN as a target for improved coproporphyrin III (CPIII) production, and exploiting phosphorylation of PrrA further improves the production of bioactive CPIII to 16.5 g L by fed-batch fermentation. Subsequent screening and engineering high-activity metal chelatases and coproheme decarboxylase results in the synthesis of various metalloporphyrins, including heme and the anti-tumor agent zincphyrin. After pilot-scale fermentation (200 L) and setting up the purification process for CPIII (purity >95%), we scaled up the production of heme and zincphyrin through enzymatic catalysis in a 5-L bioreactor, with CPIII achieving respective enzyme conversion rates of 63% and 98% and yielding 10.8 g L and 21.3 g L, respectively. Our strategy offers a solution for high-yield bioproduction of heme and other valuable porphyrins with substantial industrial and medical applications.
卟啉及其衍生物在医学、食品、能源和材料领域有着广泛的应用。在本研究中,我们通过将球形红细菌作为高效细胞工厂与酶催化相结合来生产卟啉化合物。在球形红细菌中基于全基因组CRISPRi的筛选确定hemN是提高粪卟啉III(CPIII)产量的靶点,利用PrrA的磷酸化通过补料分批发酵进一步将生物活性CPIII的产量提高到16.5 g/L。随后对高活性金属螯合酶和粪卟啉脱羧酶进行筛选和工程改造,实现了包括血红素和抗肿瘤剂锌卟啉在内的各种金属卟啉的合成。经过中试规模发酵(200 L)并建立CPIII的纯化工艺(纯度>95%)后,我们在5-L生物反应器中通过酶催化扩大了血红素和锌卟啉的生产,CPIII的酶转化率分别达到63%和98%,产量分别为10.8 g/L和21.3 g/L。我们的策略为血红素和其他具有重要工业和医学应用价值的卟啉的高产生物生产提供了一种解决方案。